AVXL · Anavex Life Sciences Corp.
Market Cap
$265.11M
Shares
92.70M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$46.38M
-7.8%
FY2025
Diluted EPS
-$0.54
-3.8%
FY2025
Operating Cash Flow
-$39.04M
-26.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.21M | $4.68M | $7.32M | $6.52M | $947K | $26K | $179.97K | $207.28K | $255.09K | $88.1K | $11.32K | -$71.83K | -$7089 | — | — | — | — | — | — | — | — | — | — | |
| $26.1M | $37.59M | $41.84M | $43.72M | $37.92M | $32.98M | $25.23M | $22.26M | $13.34M | $10.67M | $7.25M | $2.27M | $732.4K | $263.85K | $2.65M | $2.6M | $2.73M | — | — | — | — | — | — | |
| $12.47M | $13.82M | $11.04M | $12.05M | $13.07M | $9.02M | $5.86M | $6.85M | $5.99M | $5.01M | $8.33M | $4.84M | $2.24M | — | — | — | — | — | — | — | — | — | — | |
| $10M | $13.82M | $11.04M | $12.05M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $1252 | $995 | $768 | $576 | $1858 | $1657 | $910 | — | — | — | — | — | — | |
| $17.37M | $51.41M | $52.88M | $55.76M | $50.99M | $42M | -$31.09M | $29.11M | $19.33M | $15.68M | $15.59M | $7.11M | $2.97M | — | — | — | — | — | — | — | — | — | — | |
| -$17.37M | -$51.41M | -$52.88M | -$55.76M | -$50.99M | -$42M | -$31.09M | — | — | — | — | — | -$2.97M | -$2.14M | -$4.32M | -$6.18M | -$5.65M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $71.83K | $7089 | $51.34K | $138.34K | $90.25K | $284.96K | — | — | — | — | — | — | |
| $4.37M | $5.03M | $9.88M | $8.26M | $3.37M | $4.36M | $4.83M | $2.89M | $2.15M | $2.28M | $881.96K | -$5M | -$8.4M | -$1.56M | — | — | — | — | — | — | — | — | — | |
| — | -$46.38M | -$43M | -$47.5M | -$47.62M | -$37.64M | -$26.26M | -$26.21M | -$17.18M | -$13.4M | -$14.71M | -$12.11M | -$11.37M | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$1.4M | — | — | — | — | — | — | — | — | — | — | |
| -$13.02M | -$46.38M | -$43M | -$47.51M | -$47.98M | -$37.91M | -$26.28M | -$26.29M | -$17.25M | -$13.46M | -$14.74M | -$12.11M | -$9.97M | -$3.7M | -$8.3M | -$7.31M | -$8.78M | -$5.5M | -$5.35M | -$1.58M | -$25.53K | -$91.63K | -$14.4K | |
| USD/shares | -$0.15 | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | — | — | — | — | -$0.42 | -$0.65 | -$1.02 | -$0.12 | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.15 | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | — | — | — | — | -$0.42 | -$0.65 | -$1.02 | -$0.12 | -$0.29 | -$0.29 | -$0.41 | — | — | — | — | — | — |
| shares | — | 85.29M | 83.47M | 79.79M | 76.91M | 69.8M | 58.19M | 48.91M | 44.66M | 40.84M | 35.15M | 18.58M | 9.8M | 31.91M | — | — | — | — | — | — | — | — | — |
| shares | — | 85.29M | 83.47M | 79.79M | 76.91M | 69.8M | 58.19M | 48.91M | 44.66M | 40.84M | 35.15M | 18.58M | 9.8M | 31.91M | 28.17M | 25.17M | 21.44M | — | — | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 47 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.60×
EV/EBIT
—
Peer median 10.14×
P/E (TTM)
—
Peer median 10.92×
Peer medians compare against the 307 similar-size Biotechnology companies (of 515 listed).